Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biweekly docetaxel + nedaplatin for previously treated unresectable or recurrent metastatic esophageal cancer
jRCTs061210089Phase 2Suspended
- Start
- Mar 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and nedaplatin in esophageal cancer. Primary endpoint: Adverse events. Started Mar 2022; status: suspended.
02
Drugs
docetaxelnedaplatin
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on jRCTs061210089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061210089.